Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132867 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT06132867 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 12 participants.
The verdict
NCT06132867, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The main aim of this study is to compare the amount of brigatinib in the blood of healthy adults after they have swallowed one dose either as a solution or as a tablet.
Interventions
- DRUG Brigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2024-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06132867
The ClinicalTrials.gov registry entry for NCT06132867 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brigatinib is the first listed.
NCT06132867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06132867 about?
NCT06132867 is a clinical study titled "A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults". The main aim of this study is to compare the amount of brigatinib in the blood of healthy adults after they have swallowed one dose either as a solution or as a tablet.
What is the current status of trial NCT06132867?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-12-20. Estimated completion is 2024-02-17.
What interventions are being tested in trial NCT06132867?
The interventions under investigation include: Brigatinib (DRUG).
Who is sponsoring clinical trial NCT06132867?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.